UNH research seeks to quantify health outcomes based on food access, fiber intake and gut microbiota

HOUSTON — An investigational oral drug targeting the lack of brain orexin neuropeptides that characterizes narcolepsy type 1 demonstrated safety and effectiveness for the condition

Mage Bi­o­log­ics de­buted Thurs­day with a $28 mil­lion com­mit­ment from TVM Cap­i­tal Life Sci­ence and spe­cial­ty phar­ma com­pa­ny Tillotts Phar­ma. The new biotech is cen­tered

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS